The present invention relates polymorphism of GnRH receptor antagonist and a preparation method thereof. In particular, the present invention relates a type A,B,C,D crystal of 1-(4-(7-(2,6-difluorobenzyl)-3-((dimethylamino)methyl)-5-(6-methoxypyridazin-3-yl)-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)phenyl)-3-methoxyurea(compound of formula (I)) and a preparation method thereof, pharmaceutical use thereof, and type A,B,C,D crystal of formula (I) and pharmaceutical composition in the preparation of a medicament for treating and/ or preventing GnRH receptor antagonist related diseases.本發明涉及一種GnRH受體拮抗劑的多晶型及其製備方法。具體地,本發明涉及1-(4-(7-(2,6-二氟苄基)-3-((二甲胺基)甲基)-5-(6-甲氧基噠嗪-3-基)-4,6-二羰基-4,5,6,7-四氫-2H-吡唑並[3,4-d]嘧啶-2-基)苯基)-3-甲氧基脲(式(I)化合物)的多晶型A、B、C、D及其製備方法,其在醫藥組成物的應用以及該多晶型和組合物在製備治療和/或預防具有GnRH受體拮抗劑有關疾病中的用途。由於本案的圖皆為實驗數據,並非本案的代表圖。故本案無指定代表圖。
